TRACON Pharmaceuticals Inc (TCON)

[81vette]

Loaded .2101,demand growing here,was ceiling yesterday

[81vette]

Higher lows since oct 10,thru sma50,next res. sma200 .71,lots of run room on this babe until golden cross

[81vette]

ZERO BORROW,1.3m short,contracts starting

[oldstocks]

TCON listed on the % gain, most active and most trades

[TJG]

It was a lucky call and I am very grateful for the heads up...Pre-market has cooled down a bit sitting at 21 but with 26 million shares traded already it certainly appears to be headed much much higher.

[oldstocks]

Hit .376 this am, good call to get in yesterday

[Sunset Kid]

Today is gonna be epic... record volume coming in. Over 15M at 6am premarket. Where is this gonna go today?

[oldstocks]

I noticed you were in the profit from the time you posted. This has been bouncing around since the .1255 low of the year.
The high of the year was $2.19
I set my sells over $4
If the analyst raise the target we will be set.
With this new revenue i feel things changed for the better

[TJG]

Thanks some nice after hours action... I paid .1723 and we are pushing 19 now Will add more tomorrow after I look at this tonight. Thanks again

[oldstocks]

Welcome to TCON

[TJG]

Took a small position just now, so I can have a starting point... GLTA

[TJG]

Just got wind of this and it looks like its just waiting to head back to its rightful price which is substantially higher then where it currently sits... going to do some DD tonight and most likely jump on board tomorrow.

[oldstocks]

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.

“We are excited to announce the first license of our PDP to a company that recognizes the value of internalizing its clinical operations to reap the benefits of CRO-independent clinical trial implementation that we enjoy at TRACON,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We are now in a position to widely license our PDP to allow clinical stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines.”
Under the terms of the Agreement, TRACON granted a non-exclusive and non-transferable license of its PDP to the clinical stage biotech company for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals. A licensee can integrate TRACON’s configuration documentation with a widely-used software package, enabling validation and qualification of the software package, in conjunction with TRACON’s standard operation procedure documents, policies, work instructions, and clinical operation templates.

[Sunset Kid]

This price action is a joke, not selling no matter how low it goes at this point. The company hasnt been diluting like every other small cap. 30M outstanding. 9.41%% of Shares Held by All Insider. 51.92%% of Shares Held by Institutions, 57.31%% of Float Held by Institutions, 42 Number of Institutions Holding Shares

[Sunset Kid]

It's traded a years worth of volume in the last week (100M+)

[Sunset Kid]

Strong Buy! Wall Street analysts, HC Wainwright, Maxim Group and Jones Trading all give a Strong Buy over last 2 months. Avg target $4 (I bought in mid .30s a week ago,) https://www.tipranks.com/stocks/tcon/forecast

[Sunset Kid]

Strong Buy.... https://www.zacks.com/stock/research/TCON/price-target-stock-forecast?icid=quote-quote-quote_nav_tracking-zcom-left_subnav_quote_navbar-price_target_stock_forecast

[oldstocks]

4x the float manipulated! Most of the shares bought and traded were at a loss today unless.
There had to be a lot of shares shorted and reshorted today.
This should have pulled up.
Shorts have to cover sometime

[TimeFades]

Wallls to slow momentum, this one’s going higher watched level 2 shift quick. Being manipulated

[oldstocks]

I added more TCON .2253

[TimeFades]

Level 2 shifted gaining some traction heavier bud now

[oldstocks]

I took very little @ .3089
Looking for new trend up

[TimeFades]

Took some at 21

[oldstocks]

Traded 55.8 Mill, Float is 18.58 Mill

[oldstocks]

Last Change Timestamp (UTC) US:TCON Short Shares Availability
10 hours ago 2023-11-10 06:28:44.042 0
10 hours ago 2023-11-10 05:58:44.042 6,000
14 hours ago 2023-11-10 01:51:55.749 0
15 hours ago 2023-11-10 01:21:55.749 35,000
16 hours ago 2023-11-10 00:05:17.281 1,000
16 hours ago 2023-11-09 23:31:21.653 450,000
17 hours ago 2023-11-09 22:56:20.539 500,000
18 hours ago 2023-11-09 22:23:45.91 600,000
18 hours ago 2023-11-09 21:47:07.732 1,000,000
1 day ago 2023-11-08 22:36:38.559 1,200,000

[Jess070283]

Up or down? We shall see…

[TheFinalCD]

https://ih.advfn.com/stock-market/NASDAQ/tracon-pharmaceuticals-TCON/stock-news/92520604/form-10-q-quarterly-report-sections-13-or-15d

[TheFinalCD]

https://www.globenewswire.com/news-release/2023/11/09/2777785/10391/en/TRACON-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html

https://dilutiontracker.com/app/search/TCON?a=dbb88c

In July, we announced collection of the arbitration award of $22M from I-Mab Biopharma.
Expected Upcoming Milestones

Complete accrual of the ENVASARC pivotal trial in the fourth quarter of 2023 and release updated response rate data before the end of the year.

Continue to leverage TRACON’s cost-efficient, CRO-independent product development platform to generate non-dilutive capital by the end of the year.

Final data from ENVASARC pivotal trial in mid-2024.

[subslover]

NEWS
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the third quarter ended September 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

“We are on track to complete enrollment of 80 patients treated with single agent envafolimab in the ongoing pivotal ENVASARC trial this year. The data monitoring committee recommended the study continue as planned in September based on a review of 46 patients and since then more than 20 additional patients have enrolled. We expect to report updated response rate data before the end of the year, with final data anticipated mid-2024,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We also expect to license our Product Development Platform to one or more companies this year to allow them to transform their clinical operations.”

Recent Corporate Highlights

In September, we announced the ENVASARC Phase 2 pivotal trial more than exceeded the futility threshold at the second and final interim analysis and will proceed as planned. The objective response rate (ORR) in the initial 46 patients treated with single agent envafolimab was 13% by investigator review and 8.7% by blinded independent central review (BICR), all of which were confirmed responses. Envafolimab monotherapy was generally well tolerated and median duration of response by BICR was greater than six months. The primary endpoint of the study is achievement of an ORR in nine of 80 patients (11.25%) treated with envafolimab by BICR and median duration of response of greater than six months is a key secondary endpoint. Since the announcement, more than 20 additional patients have enrolled.
In July, we announced collection of the arbitration award of $22M from I-Mab Biopharma.
Expected Upcoming Milestones

Complete accrual of the ENVASARC pivotal trial in the fourth quarter of 2023 and release updated response rate data before the end of the year.
Continue to leverage TRACON’s cost-efficient, CRO-independent product development platform to generate non-dilutive capital by the end of the year.
Final data from ENVASARC pivotal trial in mid-2024.
Third Quarter 2023 Financial Results

Cash, cash equivalents and restricted cash were $7.8 million at September 30, 2023, compared to $17.5 million at December 31, 2022.
Research and development expenses for the third quarter of 2023 were $2.3 million, compared to $4.1 million for the third quarter of 2022. The decrease was primarily related to enrollment into only cohort C in the ongoing ENVASARC pivotal trial.
General and administrative expenses for the third quarter of 2023 were $1.3 million, compared to $2.3 million for the third quarter of 2022. The decrease was primarily attributable to lower legal expenses.
We received a refund of $2.0 million in arbitration success fees from our law firm in addition to the write off of approximately $0.3 million in legal fees in the third quarter of 2023.
We recorded other income of approximately $13.0 million in the third quarter of 2023 in conjunction with the collection of the arbitration award.
Net income for the third quarter of 2023 was $10.8 million, compared to a net loss of $6.4 million for the third quarter of 2022.
Conference Call Details

To access the call by phone, please register using this link and you will be provided with dial-in details.

A live webcast of the conference call will be available online from the Investor/Events and Presentation page of the Company’s website at www.traconpharma.com.

After the live webcast, a replay will remain available on TRACON’s website for 60 days.

About Envafolimab

Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor. Envafolimab was approved by the Chinese NMPA in November 2021 in adult patients with MSI-H/dMMR advanced solid tumors who failed systemic treatment and have no satisfactory alternative treatment options. In December 2019, Alphamab Oncology, 3D Medicines and TRACON entered into a collaboration whereby TRACON has the right to develop and commercialize envafolimab in soft tissue sarcoma in North America. Envafolimab is currently being studied in the ENVASARC Phase 2 pivotal trial in the United States sponsored by TRACON and a Phase 3 pivotal trial in combination with gemcitabine and oxaliplatin in advanced biliary tract cancer patients in China sponsored by TRACON’s corporate partners, Alphamab Oncology and 3D Medicines. TRACON has received orphan drug designation from the U.S. Food and Drug Administration for envafolimab for patients with soft tissue sarcoma and fast track designation from the U.S. Food and Drug Administration for envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy.

About ENVASARC (NCT04480502)

The ENVASARC pivotal trial is a multicenter, open label, randomized, non-comparative, parallel cohort study at 30 top cancer centers in the United States and the United Kingdom that began dosing in December 2020. TRACON is enrolling patients in ENVARSAC with UPS or MFS who have progressed following one or two lines of prior treatment and have

[Copilotdog]

Penny flippers wrecking which was once a thoughfilled biotech. It’s trash, don’t trade it.

[BoilerRoom]

$TCON might be a runner today

[Copilotdog]

Still going down. Probably zero.

[Copilotdog]

Out pre market. Data was bad. GL

[subslover]

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ENVASARC Phase 2 pivotal trial more than satisfied the futility threshold of 3 responses out of 46 based on the results of the second and final mandated independent data monitoring committee (IDMC) efficacy review, and the trial will continue as planned.

The IDMC reviewed interim safety and efficacy data from 46 patients enrolled into cohort C of treatment with single agent envafolimab who completed two on-treatment scans (a minimum of 12 weeks of efficacy evaluations). The objective response rate (ORR) in the initial 46 patients treated with single agent envafolimab was 13% by investigator review and 8.7% by blinded independent central review (BICR). The ORR assessed by BICR, all of which were confirmed responses, more than satisfied the prespecified futility rule and envafolimab monotherapy was generally well tolerated. Median duration of response by BICR was greater than six months. The primary endpoint of the study is achievement of an ORR in nine of 80 patients (11.25%) treated with envafolimab by BICR and median duration of response of greater than six months is a key secondary endpoint.

“Envafolimab continues to demonstrate durable single agent activity and has been generally well tolerated,” said James Freddo, M.D., TRACON’s Chief Medical Officer. “Our goal is the demonstration of nine objective responses by BICR in the 80 patient cohort of single agent envafolimab treatment.”

“We continue to believe that these data position envafolimab to become a potentially compelling treatment option for patients with the refractory sarcoma subtypes of UPS and MFS based on the ORR and tolerability data to date,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer.

The trial has enrolled more than 60 of the planned 80 patients and full accrual of the ENVASARC pivotal trial is expected in the fourth quarter of this year with final data anticipated in mid-2024.

About Envafolimab

Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor. Envafolimab was approved by the Chinese NMPA in November 2021 in adult patients with MSI-H/dMMR advanced solid tumors who failed systemic treatment and have no satisfactory alternative treatment options. In December 2019, Alphamab Oncology, 3D Medicines and TRACON entered into a collaboration whereby TRACON has the right to develop and commercialize envafolimab in soft tissue sarcoma in North America. Envafolimab is currently being studied in the ENVASARC Phase 2 pivotal trial in the United States sponsored by TRACON and a Phase 3 pivotal trial in combination with gemcitabine and oxaliplatin in advanced biliary tract cancer patients in China sponsored by TRACON’s corporate partners, Alphamab Oncology and 3D Medicines. TRACON has received orphan drug designation from the U.S. Food and Drug Administration for envafolimab for patients with soft tissue sarcoma and fast track designation from the U.S. Food and Drug Administration for envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy.

About ENVASARC (NCT04480502)

The ENVASARC pivotal trial is a multicenter, open label, randomized, non-comparative, parallel cohort study at 30 top cancer centers in the United States and the United Kingdom that began dosing in December 2020. ENVASARC is enrolling patients with UPS or MFS who have progressed following one or two lines of prior treatment and have not received an immune checkpoint inhibitor. A total of 80 patients will receive treatment with single agent envafolimab at 600 mg every three weeks. The primary endpoint is objective response rate by central review with duration of response a key secondary endpoint.

About TRACON

TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; and TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Forward-Looking Statements

Statements made in this press release regarding matters that are not historical facts are “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding TRACON’s expectations for the timing and scope of its ENVASARC Phase 2 pivotal trial as well as TRACON’s expectation for timely achievement of expected endpoints and goals, the availability and expected results of clinical data and the timing of future reviews of data by the IDMC and BICR, continued timely accrual in the ENVASARC Phase 2 pivotal

[Copilotdog]

Any company with CON in the name is bad juju.

[Copilotdog]

Buy AUPH. This is trash. CEO is a dilution captain.

[microcapbiotech]

Meant to say: Started a position today (8-24-23) at 25 cents. A bit risky, as a reverse SPLIT may be coming soon, also they just have cash to go through Q1 2024, but they are supposed to announce trial data Q3 2023, so pretty much, make or break.

[microcapbiotech]

Started a position today (8-24-23) at 25 cents. A bit risky, as a reverse may be coming soon, also they just have cash to go through Q1 2024, but they are supposed to announce trial data Q3 2023, so pretty much, make or break.

[Copilotdog]

Is this going to bounce?

[Monksdream]

It is what I do
Practically a gimme

[Copilotdog]

Covered! Boom! Love these shit bios to short. Sorry longs.

[Copilotdog]

Short at top, .37c. Let’s go to .25c next week!!

[Copilotdog]

This company I thought had a good ceo. He must have messed up.

[Copilotdog]

Seems $8 or even $4 would never come again. Maybe .60c

[AJ Freely]

$TCON-video coverage
🧙‍♂️Zidar On Top & Hot Penny Stock~
3 Bio-techs all working with Oncology and cancer drugs, each has a Very Hot Chart and Catalyst.
Though none of the catalysts are drug related. 🙄

[Copilotdog]

Think they got total of 24m 13.5 + the 9 from the drug.

[pilotnick]

this is what they got: I-Mab (NASDAQ: IMAB) said an arbitration tribunal awarded no damages to Tracon Pharmaceuticals (NASDAQ: TCON) related to a collaboration agreement but the company would have to pay part of Tracon's legal fees of ~$13.5M.

so if TCON got half their legal fees paid TCON is still out $6.5 million almost their market cap!

[Copilotdog]

They got paid. But it’s still going down. Probably bad drug line

[Copilotdog]

Are they getting paid by IMAB? Looks like legal trouble using a spy

[Copilotdog]

Damn. This was $12 once. What a mess these bios are.